Warner-Lambert/Neurex SNX-111 pivotal trial in head trauma suspends patient enrollment.
Executive Summary
WARNER-LAMBERT/NEUREX SNX-111 HEAD TRAUMA PHASE III ENROLLMENT SUSPENDED following unblinding of results from earlier trials, the companies announced July 28. The Phase III head trauma study was planned as an 800-patient trial but only a few subjects have been enrolled, Neurex said. The recently received data "must be carefully analyzed to evaluate the relative risk in relation to the benefit of administering SNX-111 in accordance with the current Warner-Lambert protocol," Neurex said. The company noted that treating patients with head trauma "is particularly difficult as they often have other multiple and serious injuries."
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth